The drug makers Moderna and Merck report a new experimental vaccine treatment shows promising signs of preventing skin cancer from returning or spreading in high-risk melanoma patients. The first-of-its-kind therapy could herald a powerful new approach for treating other cancers. It relies on the same mRNA technology that led to the rapid development of lifesaving vaccines during the COVID pandemic. This comes after the Trump administration slashed a half-billion dollars’ worth of contracts and grants for mRNA vaccine development projects targeting respiratory viruses.